Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results ...
Jan. 13, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced ...
REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...
Nevro shares gained after the company said it expects to see fourth-quarter and full-year 2024 revenue higher than analysts' expectations. The medical-device company's stock was up 16%, to $3.83 ...
Hosted on MSN23d
Nevro Stock Falls Despite Q4 Sales Beat on Strong SCS DemandNevro NVRO recently announced preliminary revenues for fourth-quarter and full year 2024. Investors seem to panic eyeing the preliminary results, as the company’s shares declined nearly 8% at ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Nevro (NYSE:NVRO) today reported preliminary fourth-quarter revenue numbers were down year-over-year but were better than Wall Street analyst expectations. The developer of implantable spinal cord ...
Jan. 13, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback